NEW YORK (June 12, 2019)—TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments,
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant
Every year, more than ten million people worldwide contract tuberculosis (TB) and in 2017, 1.6 million people died as a
GENEVA (May 22, 2019) – This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health
Two of TB Alliance’s academic collaborators presented findings from scientific research related to drug-resistant forms of tuberculosis at the American Thoracic
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
Joint Statement for Multi-stakeholder Hearing on UHC: Product Development Partnerships “We face a collective challenge in ensuring that everyone—regardless where
We spoke with Karl Hofmann, president and CEO of Population Services International (PSI), to hear about his time serving as
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan
March 20, 2019 – Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis, released today, outlines what is needed
